SynthesisDrugs2011
The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.
Synthesis in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Sleep disorders in Parkinson's disease, an early and multiple problem.NPJ Parkinson's disease · 2024Article
- Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy.Mini reviews in medicinal chemistry · 2024Review
- Review
- [Parkinson's disease: a bibliographic update of psychosocial aspects].Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022Review
- Parkinson and depression: review and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Bipolar spectrum disorders in neurologic disorders.Frontiers in psychiatry · 2022Review
- Therapeutic strategies in the early stages of Parkinson's disease: a cross-sectional evaluation of 15 years' experience with a large cohort of Romanian patients.Neuropsychiatric disease and treatment · 2019Article
- The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson's Disease (PD) and Major Depressive Disorder (MDD).Frontiers in pharmacology · 2019Review
- Review
- Early Life Stress, Depression And Parkinson's Disease: A New Approach.Molecular brain · 2018Review
- Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.Current neurology and neuroscience reports · 2017Review
- The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease.Parkinsonism & related disorders · 2017Article
- Effects of a combination treatment of KD5040 andBMC complementary and alternative medicine · 2017Article
- A practical approach to detection and treatment of depression in Parkinson disease and dementia.Neurology. Clinical practice · 2017Review
- Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease.Acta neurologica Scandinavica · 2017Article
- Neuropsychiatric Issues in Parkinson's Disease.Current neurology and neuroscience reports · 2016Review
- The longitudinal impact of depression on disability in Parkinson disease.International journal of geriatric psychiatry · 2016Article
- Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.BMC complementary and alternative medicine · 2014Article
- Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.Neuropsychiatric disease and treatment · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive disorders as well as depressive symptoms are common in Parkinson's disease (PD) and an important factor affecting quality of life. Treatment of depressive symptoms not only improves mood but is also associated with improvement of motor symptoms, disability and cognitive symptoms. Currently, dopamine agonists are being suggested as an alternative to antidepressants for the treatment of depression in PD. The aim of this article is to systematically review the efficacy of dopamine agonists in the treatment of depression in PD. Since 1983, 19 studies have reported on the effects of dopamine agonists on depressive disorder, depressive symptoms or mood in PD. To date, no double-blind, placebo-controlled, randomized controlled trial of the treatment of major depressive disorder in PD with a dopamine agonist has been conducted. Studies of the effects of treatment with dopamine agonists on depressive symptoms in PD, or on mood in non-depressed PD patients, have yielded inconclusive results. Most studies are not designed to test effects on mood and are limited by methodological flaws. It can be concluded that, although the preliminary evidence of the effects on mood and depression in PD is interesting and in need of further study, there is as yet insufficient evidence to recommend dopamine agonists in the treatment of either depressive disorder or depressive symptoms in patients with PD. Treatment of depressive disorder and clinically relevant depressive symptoms should be based on pharmacological or non-pharmacological interventions with known efficacy in this population, such as citalopram, nortriptyline, desipramine or cognitive behavioural therapy. This strategy has the additional advantage of enabling the clinician to treat depressive symptoms independently of motor symptoms, thus avoiding potential complications of dopaminergic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.